Health Care/Hospital APAC News & Press Release Distribution

Health Care/Hospital

All
Global

Mobile Medical Imaging Systems Improving Care Accessibility and Convenience for Patients

Portability and cost-effectiveness are key factors propelling the adoption of mobile medical imaging technology globally, says Frost & Sullivan SAN ANTONIO, Feb. 9, 2022 /PRNewswire/ -- Frost & Sullivan's recent analysis finds that the drawbacks of traditional medical imaging platforms are drivin...

2022-02-09 20:00 1385

Mobile Medical Imaging Systems Improving Care Accessibility and Convenience for Patients

Best-in-class companies in Asia-Pacific Recognized by the Frost & Sullivan Best Practices

12 organizations lauded for their exemplary performance and valuable contributions in shaping new trends SINGAPORE, Feb. 9, 2022 /PRNewswire/ -- Frost & Sullivan's Best Practices Awards commend leading companies that have accomplished innovative or disruptive breakthroughs and have continu...

2022-02-09 19:17 1442

Best-in-class companies in Asia-Pacific Recognized by the Frost & Sullivan Best Practices

Sirnaomics Launches Phase I Clinical Trial of RNAi Therapeutic STP707 Delivered Systemically for the Treatment of Solid Tumors

HONG KONG, Feb. 9, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced the start of a Phase I clinical trial for evaluation of the safety, tolerability and anti-...

2022-02-09 17:10 1750

Hummingbird Bioscience Publishes Preclinical Data Demonstrating Therapeutic Potential of HMBD-002 in VISTA-expressing Cancers

HOUSTON and SINGAPORE, Feb. 9, 2022 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets in cancer and autoimmune disease, today announced the publication of preclinical data for HMBD-002, a nov...

2022-02-09 17:00 1502

Glenmark and SaNOtize announce positive Results from Phase 3 Clinical Trial of NONS (FabiSpray®) in Non-Hospitalized Adult Indian Patients with COVID-19

* Phase 3 trial in India met the key endpoints and demonstrated reduction of viral load of 94% in 24 hours and 99% in 48 hours. * NONS was safe and well tolerated in COVID-19 patients. * Glenmark received manufacturing and marketing approval from India's drug regulator for Nitric Oxide Nasal...

2022-02-09 15:47 1967

China Life Singapore Aims to Expand Agency Channel to 100 Agents with Enhanced New Business Model

SINGAPORE, Feb. 9, 2022 /PRNewswire/ -- China Life Insurance (Singapore) Pte Ltd ("China Life Singapore") successfully held the first Agency Channel annual award ceremony on27 January 2022. In strict compliance with COVID-19 safe management measures, the award ceremony brought together the elites...

2022-02-09 12:52 2169

COLOPLAST SINGAPORE LAUNCHES SENSURA MIO(R), A PRODUCT MADE WITH THE LATEST TECHNOLOGY FOR OSTOMY AND STOMA CARE

* SenSura® Mio features BodyFit technology, an elastic adhesive technology fit for all peristomal body profiles. SINGAPORE, Feb. 9, 2022 /PRNewswire/ -- Coloplast, one of the world's leading manufacturers of stoma care products launches its latest product innovation, the SenSura®Mio in Singapor...

2022-02-09 12:44 1713

Luye Pharma Grants Laboratorio LIBRA Exclusive Marketing Rights for Seroquel and Seroquel XR in Chile

SHANGHAI, Feb. 9, 2022 /PRNewswire/ -- Luye Pharma Group announced today that it has entered into an agreement with Laboratorio LIBRA, under which the company grants Laboratorio LIBRA the exclusive rights to market its innovative CNS (central nervous system) drugs Seroquel (quetiapine fumarate, i...

2022-02-09 11:57 1728

CStone announced new drug approval of China's first IDH1 inhibitor TIBSOVO® (ivosidenib tablets) as a new precision therapy for patients with acute myeloid leukemia

* TIBSOVO®, a first-in-class drug, is approved for adult patients with relapsed/refractory acute myeloid leukemia (R/R AML) who have a susceptible IDH1 mutation * Clinical study data showed that TIBSOVO® had robust clinical efficacy and a well-tolerated and manageable safety profile in Chines...

2022-02-09 11:53 3142

Bugworks Research Inc. secures US$18M Series B1 Funding from Reputed Global Investor Syndicate (The EU, UK, Japan, South Africa & India), led by Lightrock India

This Funding will advance highly differentiated assets in the dual areas of Antimicrobial Resistance (AMR) and Immuno-Oncology (IO) BANGALORE, India, SARATOGA, Calif. and ADELAIDE, Australia, Feb. 9, 2022 /PRNewswire/ -- Bugworks Research, a clinical stage multi-indication therapeutics company, ...

2022-02-09 10:00 9650

Bugworks Research Inc. secures US$18M Series B1 Funding from Reputed Global Investor Syndicate (The EU, UK, Japan, South Africa & India), led by Lightrock India

Bactiguard presents focused growth strategy and sets new long-term financial targets

STOCKHOLM, Feb. 9, 2022 /PRNewswire/ -- Bactiguard presents new long-term financial targets in connection with the year-end report for 2021. The new financial targets relate to growth and profitability, with annual revenues of at least1 billion SEK and annual EBITDA of at least 400 million SEK in...

2022-02-09 07:27 1798

First Proton Therapy Treatment Delivered in Southeast Asia at Her Royal Highness Princess Maha Chakri Sirindhorn Proton Center, Thailand

BANGKOK, Feb. 9, 2022 /PRNewswire/ -- Varian, a Siemens Healthineers company, today announced that Her Royal Highness Princess Maha Chakri Sirindhorn Proton Center has begun treating patients with its new Varian ProBeam® proton therapy system, the first of its kind inThailand and Southeast Asia. ...

2022-02-09 05:15 2767

Bactiguard and Zimmer Biomet expand global license partnership

STOCKHOLM, Feb. 9, 2022 /PRNewswire/ -- Bactiguard and Zimmer Biomet have today agreed to expand the global license partnership, that was initiated in 2019, to cover multiple product segments. The extended exclusive license agreement covers implants for joint reconstruction (hips and knees), spo...

2022-02-09 04:10 1532

Cambrex Recognized with 2022 CMO Leadership Awards for the 8th Consecutive Year

EAST RUTHERFORD, N.J., Feb. 8, 2022 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), announced today that it has been recognized by the annual CMO (Contract Manufacturing Organization) Leadership Awards in the categories of Quality and Service....

2022-02-08 22:30 2324

WuXi Biologics Statement

SHANGHAI, Feb. 8, 2022 /PRNewswire/ -- We have been made aware of a recent U.S. Commerce Department announcement that two WuXi Biologics (Cayman) subsidiaries inShanghai and Wuxi will be added to the department's "Unverified List" (UVL) on February 8, 2022. We understand that the reason for this a...

2022-02-08 11:08 3111

Singapore-Johor VTL resumes with COVID-19 test results issued by Jebhealth

SINGAPORE, Feb. 8, 2022 /PRNewswire/ -- With the resumption of the land VTL betweenSingapore and Johor Bahru on Jan 21, about 2,000 travellers are expected to cross the causeway each day, in hope that we can eventually scale up to the normal 300,000 daily commutes. Many would be meeting their lov...

2022-02-08 07:00 3068

mRNA COVID-19 Vaccines are Safe for People with Cancer According to New Study in JNCCN

Researchers at Fox Chase Cancer Center conducted the largest published, peer-reviewed, study to-date examining the short-term adverse effects of mRNA COVID-19 vaccination in patients with cancer—finding they experienced no more, and no different, side effects compared to non-cancer patients. PLY...

2022-02-08 05:11 1999

Covaris AFA-energetics™ Enables True Automated Total Nucleic Acid Extraction and Purification Workflows from FFPE Tissues

A fully automated, high-throughput deparaffinization and total Nucleic Acids extraction and purification kit for FFPE samples WOBURN, Mass., Feb. 7, 2022 /PRNewswire/ -- Covaris, LLC ("Covaris" or "the Company"), a manufacturer of advanced tools enabling life science innovations, announced the l...

2022-02-07 23:00 2637

Ascletis Announces Positive Data of Oral Double Prodrug ASC10 and Its Antiviral Nucleoside Analog ASC10-A Against Omicron Variant

* ASC10-A demonstrated strong in vitro antiviral activity against multiple SARS-CoV-2 virus variants including Omicron * By applying a double prodrug strategy, ASC10's permeability in Caco-2 cells and ASC10's oral bioavailability in monkeys were 3.2-fold and 2.3-fold of Molnupiravir, respecti...

2022-02-07 19:00 2353

'2022 Sunhak Peace Prize Focuses on Vaccine Equity'

SEOUL, South Korea, Feb. 7, 2022 /PRNewswire/ -- On February 7, 2022, the Sunhak Peace Prize Committee (ChairmanJose Manuel Barroso, former President of the European Commission) will announce the 2022 Sunhak Peace Prize laureates are DameSarah Catherine Gilbert (age 59), Professor of Vaccinology ...

2022-02-07 18:00 2518

'2022 Sunhak Peace Prize Focuses on Vaccine Equity'

1 ... 230 231 232233234 235 236 ... 553